Abstract
Pyridoxal-5′-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for >4% of classified enzymatic activities of the cell. It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases. As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP. In addition, PLP is required for the catabolism of homocysteine by transsulfuration. Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases. During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer. Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms. More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions. Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC). Here, we will discuss the clinical relevance of vitamin B6 metabolism as a prognostic factor in cancer patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- BCG:
-
Bacillus Calmette–Guérin
- MTHFR:
-
methylenetetrahydrofolate reductase
- NSCLC:
-
non-small cell lung carcinoma
- PDXK:
-
pyridoxal kinase
- PDXP:
-
pyridoxal phosphatase
- PL:
-
pyridoxal
- PLP:
-
pyridoxal-5′-phosphate
- PM:
-
pyridoxamine
- PMP:
-
pyridoxamine-5′-phosphate
- PN:
-
pyridoxine
- PNP:
-
pyridoxine-5′-phosphate
- TS:
-
thymidylate synthase.
References
Gyorgy P, Eckardt RE . Further investigations on vitamin B(6) and related factors of the vitamin B(2) complex in rats. Parts I and II. Biochem J 1940; 34: 1143–1154.
Toney MD . Reaction specificity in pyridoxal phosphate enzymes. Arch Biochem Biophys 2005; 433: 279–287.
Fedde KN, Whyte MP . Alkaline phosphatase (tissue-nonspecific isoenzyme) is a phosphoethanolamine and pyridoxal-5′-phosphate ectophosphatase: normal and hypophosphatasia fibroblast study. Am J Hum Genet 1990; 47: 767–775.
Roth-Maier DA, Kettler SI, Kirchgessner M . Availability of vitamin B6 from different food sources. Int J Food Sci Nutr 2002; 53: 171–179.
Bairoch A . The ENZYME data bank. Nucleic Acids Res 1994; 22: 3626–3627.
Selhub J . Homocysteine metabolism. Annu Rev Nutr 1999; 19: 217–246.
Tucker KL, Olson B, Bakun P, Dallal GE, Selhub J, Rosenberg IH . Breakfast cereal fortified with folic acid, vitamin B-6, and vitamin B-12 increases vitamin concentrations and reduces homocysteine concentrations: a randomized trial. Am J Clin Nutr 2004; 79: 805–811.
Manegold C, Hoffmann GF, Degen I, Ikonomidou H, Knust A, Laass MW et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 2009; 32: 371–380.
Chang YC, Scott RD, Graves DJ . Function of pyridoxal 5'-phosphate in glycogen phosphorylase: a model study using 6-fluoro-5'-deoxypyridoxal- and 5′-deoxypyridoxal-reconstituted enzymes. Biochemistry 1987; 26: 360–367.
Nandi DL . Delta-aminolevulinic acid synthase of rhodopseudomonas spheroides. Binding of pyridoxal phosphate to the enzyme. Arch Biochem Biophys 1978; 188: 266–271.
Schnackerz KD, Benesch RE, Kwong S, Benesch R, Helmreich EJ . Specific receptor sites for pyridoxal 5'-phosphate and pyridoxal 5'-deoxymethylenephosphonate at the alpha and beta NH2-terminal regions of hemoglobin. J Biol Chem 1983; 258: 872–875.
Bourquin F, Capitani G, Grutter MG . PLP-dependent enzymes as entry and exit gates of sphingolipid metabolism. Protein Sci 2011; 20: 1492–1508.
Clayton PT . B6-responsive disorders: a model of vitamin dependency. J Inherit Metab Dis 2006; 29: 317–326.
Lumeng L, Li TK . Vitamin B6 metabolism in chronic alcohol abuse. Pyridoxal phosphate levels in plasma and the effects of acetaldehyde on pyridoxal phosphate synthesis and degradation in human erythrocytes. J Clin Invest 1974; 53: 693–704.
Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006; 12: 307–309.
Friedman MA, Resnick JS, Baer RL . Subepidermal vesicular dermatosis and sensory peripheral neuropathy caused by pyridoxine abuse. J Am Acad Dermatol 1986; 14: 915–917.
Gdynia HJ, Muller T, Sperfeld AD, Kuhnlein P, Otto M, Kassubek J et al. Severe sensorimotor neuropathy after intake of highest dosages of vitamin B6. Neuromuscul Disord 2008; 18: 156–158.
Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309: 445–448.
Dalton K, Dalton MJ . Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987; 76: 8–11.
Hanahan D, Weinberg RA . Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
Galluzzi L, Vitale I, Kroemer G . Past, present, and future of molecular and cellular oncology. Front Oncol 2011; 1: 1.
Fritz V, Fajas L . Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene 2010; 29: 4369–4377.
Haberkorn U, Markert A, Mier W, Askoxylakis V, Altmann A . Molecular imaging of tumor metabolism and apoptosis. Oncogene 2011; 30: 4141–4151.
Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 2013; 32: 1475–1487.
Stoerk HC . Growth retardation of lymphosarcoma implants in pyridoxine deficient rats by testosterone and cortisone. Proc Soc Exp Biol Med 1950; 74: 798–800.
Mihich E . Host defense mechanisms in the regression of sarcoma 180 in pyridoxine-deficient mice. Cancer Res 1962; 22: 218–227.
Littman ML, Taguchi T, Shimizu Y . Retarding effect of vitamin deficient and cholesterol free diets on growth of sarcoma 180. Proc Soc Exp Biol Med 1964; 116: 95–101.
Mihich E, Nichol CA . Antitumor effects of methylglyoxal-bis(N-4-methylthiosemicarbazone) and their potentiation in pyridoxine-deficient animals. Cancer Res 1965; 25: 794–801.
Yuspa SH, Blaustein AS . Inhibitory effect of pyridoxine deficiency on growth of a transplanted tumor in rats. Proc Soc Exp Biol Med 1966; 123: 398–403.
Riggs TR, Coyne B, Christensen HN . Intensification of the cellular accumulation of amino acids by pyridoxal. Biochim Biophys Acta 1953; 11: 303–304.
Christensen HN, Riggs TR, Coyne BA . Effects of pyridoxal and indoleacetate on cell uptake of amino acids and potassium. J Biol Chem 1954; 209: 413–427.
Tryfiates GP, Morris HP . Effect of pyridoxine deficiency on tyrosine transaminase activity and growth of four Morris hepatomas. J Natl Cancer Inst 1974; 52: 1259–1262.
Tryfiates GP, Shuler JK, Hefner MH, Morris HP . Effect of B6 deficiency on hepatoma 7794A growth rate: activities of tyrosine transaminase and serine dehydratase before and after induction by hydrocortisone. Eur J Cancer 1974; 10: 147–154.
Tryfiates GP . Effect of pyridoxine availability on the activity of serine dehydratase of normal liver, host liver, and three Morris hepatomas. J Natl Cancer Inst 1975; 54: 171–172.
Tryfiates GP . Effect of pyridoxine on the growth of Morris hepatoma No. 7288Ctc and enzyme activity. Oncology 1976; 33: 209–211.
Schwan TJ, Tieckelmann B, Holland JF, Bryant B . 2,4-dimethyl-5-hydroxymethylpyrimidine, a pyridoxol antagonist. J Med Chem 1965; 8: 750–753.
Semeraro N, Grimaldi T, La Pesa M, Restuccia P . Study of the influence of some antimetabolites of vitamin B 6 on the appearance and development of (solid) IRE reticulo-sarcoma in the rat. II. Isonicotinic acid hydrozide (INH). Pathologica 1970; 62: 133–137.
Grimaldi T, La Pesa M, Curci E, Semeraro N . Latest research on the effect of desoxypyridoxine on the formation and development of experimental neoplasms. I. Ascitic tumors in mice. Pathologica 1971; 63: 89–91.
Korytnyk W, Srivastava SC . Synthesis and physicochemical and biological properties of 6-halogen-substituted vitamin B 6 analogs. J Med Chem 1973; 16: 638–642.
Korytnyk W, Ghosh AC, Potti PG, Srivastava SC . Synthesis and biological properties of 4-amino- and 4-bromo-4-norpyridoxol. New approaches for the modification of the 4 position of vitamin B6. J Med Chem 1976; 19: 999–1002.
Korytnyk W, Angelino N . Vitamin B6 antagonists obtained by replacing or modifying the 2-methyl group. J Med Chem 1977; 20: 745–749.
Koss LG, Lavin P . Studies of experimental bladder carcinoma in Fischer 344 female rats. I. Induction of tumors with diet low in vitamin B6 containing N-2-fluorenylacetamide after single dose of cyclophosphamide. J Natl Cancer Inst 1971; 46: 585–595.
Tryfiates GP . Control of tumor growth by pyridoxine restriction or treatment with an antivitamin agent. Cancer Detect Prev 1981; 4: 159–164.
Tryfiates GP, Morris HP, Sonidis GP . Vitamin B6 and cancer (review). Anticancer Res 1981; 1: 263–267.
DiSorbo DM, Litwack G . Vitamin B6 kills hepatoma cells in culture. Nutr Cancer 1982; 3: 216–222.
DiSorbo DM, Nathanson L . High-dose pyridoxal supplemented culture medium inhibits the growth of a human malignant melanoma cell line. Nutr Cancer 1983; 5: 10–15.
DiSorbo DM, Wagner R, Nathanson L . In vivo and in vitro inhibition of B16 melanoma growth by vitamin B6. Nutr Cancer 1985; 7: 43–52.
Shultz TD, Santamaria AG, Gridley DS, Stickney DR, Slater JM . Effect of pyridoxine and pyridoxal on the in vitro growth of human malignant melanoma. Anticancer Res 1988; 8: 1313–1318.
Trebukhina RV, Mikhal'tsevich GN . Vitamin B6 metabolism in mice with Ehrlich ascites tumor. Vopr Pitan 1982; 1: 40–44.
Gridley DS, Stickney DR, Nutter RL, Slater JM, Shultz TD . Suppression of tumor growth and enhancement of immune status with high levels of dietary vitamin B6 in BALB/c mice. J Natl Cancer Inst 1987; 78: 951–959.
Nikonova TV, Draudin-Krylenko VA, Bukin IuV, Turusov VS . Protective action of nicotinamide and pyridoxine on the initiation stage of carcinogenesis induced in mice by procarbazine. Eksp Onkol 1988; 10: 17–19.
Draudin-Krylenko VA, Bukin IuV, Nikonova TV . Anticarcinogenic action of vitamins PP and B6 in the natulan initiation of malignant growth in mice. Vopr Onkol 1989; 35: 34–38.
Ha C, Kerkvliet NI, Miller LT . The effect of vitamin B-6 deficiency on host susceptibility to Moloney sarcoma virus-induced tumor growth in mice. J Nutr 1984; 114: 938–948.
Ha C, Miller LT, Kerkvliet NI . The effect of vitamin B6 deficiency on cytotoxic immune responses of T cells, antibodies, and natural killer cells, and phagocytosis by macrophages. Cell Immunol 1984; 85: 318–329.
Gebhard KJ, Gridley DS, Stickney DR, Shulz TD . Enhancement of immune status by high levels of dietary vitamin B-6 without growth inhibition of human malignant melanoma in athymic nude mice. Nutr Cancer 1990; 14: 15–26.
Folkers K, Morita M, McRee J . The activities of coenzyme Q10 and vitamin B6 for immune responses. Biochem Biophys Res Commun 1993; 193: 88–92.
Meisler NT, Nutter LM, Thanassi JW . Vitamin B6 metabolism in liver and liver-derived tumors. Cancer Res 1982; 42: 3538–3543.
Williams RD, Nixon DW, Merrill AH . Comparison of serine palmitoyltransferase in Morris hepatoma 7777 and rat liver. Cancer Res 1984; 44: 1918–1923.
Tryfiates GP . Metabolic interconversions of pyridoxine by Morris hepatoma No. 7777 cells. Synthesis of a novel metabolite. Anticancer Res 1983; 3: 53–58.
Molina A, Oka T, Munoz SM, Chikamori-Aoyama M, Kuwahata M, Natori Y . Vitamin B6 suppresses growth and expression of albumin gene in a human hepatoma cell line HepG2. Nutr Cancer 1997; 28: 206–211.
Komatsu SI, Watanabe H, Oka T, Tsuge H, Nii H, Kato N . Vitamin B-6-supplemented diets compared with a low vitamin B-6 diet suppress azoxymethane-induced colon tumorigenesis in mice by reducing cell proliferation. J Nutr 2001; 131: 2204–2207.
Komatsu S, Watanabe H, Oka T, Tsuge H, Kat N . Dietary vitamin B6 suppresses colon tumorigenesis, 8-hydroxyguanosine, 4-hydroxynonenal, and inducible nitric oxide synthase protein in azoxymethane-treated mice. J Nutr Sci Vitaminol (Tokyo) 2002; 48: 65–68.
Komatsu S, Yanaka N, Matsubara K, Kato N . Antitumor effect of vitamin B6 and its mechanisms. Biochim Biophys Acta 2003; 1647: 127–130.
Shimada D, Fukuda A, Kawaguchi H, Kato N, Yoshida H, Kanouchi H et al. Effect of high dose of pyridoxine on mammary tumorigenesis. Nutr Cancer 2005; 53: 202–207.
Shimada D, Fukuda A, Kanouchi H, Matsumoto M, Oka T . Vitamin B6 suppresses growth of the feline mammary tumor cell line FRM. Biosci Biotechnol Biochem 2006; 70: 1038–1040.
Kulcsar G . Inhibition of the growth of a murine and various human tumor cell lines in culture and in mice by mixture of certain substances of the circulatory system. Cancer Biother 1995; 10: 157–176.
Kulcsar G, Gaal D, Kulcsar PI, Schulcz A, Czompoly T . A mixture of amino acids and other small molecules present in the serum suppresses the growth of murine and human tumors in vivo. Int J Cancer 2013; 132: 1213–1221.
Hofsli E, Waage A . Effect of pyridoxine on tumor necrosis factor activities in vitro. Biotherapy 1992; 5: 285–290.
Komatsu S, Isobe M, Yanaka N, Kato N . A high-fat diet enhances the inhibitory effect of dietary vitamin B6 on colon cell proliferation in mice. Oncol Rep 2005; 14: 265–269.
Rosenthal GA . L-canaline: a potent antimetabolite and anti-cancer agent from leguminous plants. Life Sci 1997; 60: 1635–1641.
Swaffar DS, Ang CY . Growth inhibitory effect of L-canavanine against MIA PaCa-2 pancreatic cancer cells is not due to conversion to its toxic metabolite canaline. Anticancer Drugs 1999; 10: 113–118.
Kanellis P, Gagliardi M, Banath JP, Szilard RK, Nakada S, Galicia S et al. A screen for suppressors of gross chromosomal rearrangements identifies a conserved role for PLP in preventing DNA lesions. PLoS Genet 2007; 3: e134.
Takeuchi PL, Antunes LM, Takahashi CS . Evaluation of the clastogenicity and anticlastogenicity of vitamin B6 in human lymphocyte cultures. Toxicol In Vitro 2007; 21: 665–670.
Mehta R, Dedina L, O'Brien PJ . Rescuing hepatocytes from iron-catalyzed oxidative stress using vitamins B1 and B6. Toxicol In Vitro 2011; 25: 1114–1122.
Kayashima T, Tanaka K, Okazaki Y, Matsubara K, Yanaka N, Kato N . Consumption of vitamin B6 reduces colonic damage and protein expression of HSP70 and HO-1, the anti-tumor targets, in rats exposed to 1,2-dimethylhydrazine. Oncol Lett 2011; 2: 1243–1246.
Garg MB, Ackland SP . Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. Cancer Chemother Pharmacol 2011; 67: 963–966.
D'Agostini F, Fiallo P, Ghio M, De Flora S . Chemoprevention of doxorubicin-induced alopecia in mice by dietary administration of L-cystine and vitamin B6. Arch Dermatol Res 2013; 305: 25–34.
Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012; 2: 257–269.
Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P et al. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle 2013, (In press).
Gailani S, Roque AL, Holland JF . The effect of pyridoxine deficiency on carcinoid syndrome. Study of a case of metastatic bronchial adenoma treated with induced vitamin B6 deficiency. Ann Intern Med 1966; 65: 1044–1050.
Gailani SD, Holland JF, Nussbaum A, Olson KB . Clinical and biochemical studies of pyridoxine deficiency in patients with neoplastic diseases. Cancer 1968; 21: 975–988.
Potera C, Rose DP, Brown RR . Vitamin B6 deficiency in cancer patients. Am J Clin Nutr 1977; 30: 1677–1679.
Ramaswamy PG, Natarajan R . Vitamin B6 status in patients with cancer of the uterine cervix. Nutr Cancer 1984; 6: 176–180.
Inculet RI, Norton JA, Nichoalds GE, Maher MM, White DE, Brennan MF . Water-soluble vitamins in cancer patients on parenteral nutrition: a prospective study. JPEN J Parenter Enteral Nutr 1987; 11: 243–249.
Pais RC, Vanous E, Hollins B, Faraj BA, Davis R, Camp VM et al. Abnormal vitamin B6 status in childhood leukemia. Cancer 1990; 66: 2421–2428.
Tryfiates GP, Bishop RE, Murgo AJ . Vitamin B6 and cancer: a novel pyridoxal 5-phosphate conjugate in tumor cells and blood of cancer patients. Anticancer Res 1991; 11: 1281–1284.
Tryfiates GP, Gannett PM, Bishop RE, Shastri PK, Ammons JR, Arbogast JG . Vitamin B6 and cancer: synthesis and occurrence of adenosine-N6-diethylthioether-N-pyridoximine-5'-phosphate, a circulating human tumor marker. Cancer Res 1996; 56: 3670–3677.
Wolf H, Brown RR . Tryptophan metabolism in bladder cancer patients from Copenhagen. Scand J Urol Nephrol 1979; 13: 143–148.
Baker H, Frank O, Chen T, Feingold S, DeAngelis B, Baker ER . Elevated vitamin levels in colon adenocarcinoma as compared with metastatic liver adenocarcinoma from colon primary and normal adjacent tissue. Cancer 1981; 47: 2883–2886.
Atukorala TM, Dickerson JW, Basu TK, McElwain TJ . Longitudinal studies of nutritional status in patients having chemotherapy for testicular teratomas. Clin Oncol 1983; 9: 3–10.
Baker H, Marcus SL, Petrylak DP, Frank O, DeAngelis B, Baker ER et al. Effect of interleukin-2 on some micronutrients during adoptive immunotherapy for various cancers. J Am Coll Nutr 1992; 11: 482–486.
Kurashige S, Akuzawa Y, Fujii N, Kishi S, Takeshita M, Miyamoto Y . Effect of vitamin B complex on the immunodeficiency produced by surgery of gastric cancer patients. Jpn J Exp Med 1988; 58: 197–202.
Rauf M, Gleason C, Nooka AK, Husman A, Waller EK . Treatment of severe neutropenia with high-dose pyridoxine in a patient with chronic graft versus host disease and squamous cell carcinoma: a case report. J Med Case Rep 2011; 5: 372.
Tryfiates GP, Bishop RE . Vitamin B6 and cancer: adenosine-N6-diethylthioether N1-pyridoximine 5′-PO4, a circulating human tumor marker. Anticancer Res 1995; 15: 379–383.
Byar D, Blackard C . Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 1977; 10: 556–561.
Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI . Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151: 21–26.
Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1995; 27: 110–116.
King WD, Ho V, Dodds L, Perkins SL, Casson RI, Massey TE . Relationships among biomarkers of one-carbon metabolism. Mol Biol Rep 2012; 39: 7805–7812.
de Vogel S, Dindore V, van Engeland M, Goldbohm RA, van den Brandt PA, Weijenberg MP . Dietary folate, methionine, riboflavin, and vitamin B-6 and risk of sporadic colorectal cancer. J Nutr 2008; 138: 2372–2378.
Harnack L, Jacobs DR, Nicodemus K, Lazovich D, Anderson K, Folsom AR . Relationship of folate, vitamin B-6, vitamin B-12, and methionine intake to incidence of colorectal cancers. Nutr Cancer 2002; 43: 152–158.
Lim U, Schenk M, Kelemen LE, Davis S, Cozen W, Hartge P et al. Dietary determinants of one-carbon metabolism and the risk of non-Hodgkin’s lymphoma: NCI-SEER case-control study, 1998-2000. Am J Epidemiol 2005; 162: 953–964.
Lim U, Weinstein S, Albanes D, Pietinen P, Teerenhovi L, Taylor PR et al. Dietary factors of one-carbon metabolism in relation to non-Hodgkin lymphoma and multiple myeloma in a cohort of male smokers. Cancer Epidemiol Biomarkers Prev 2006; 15: 1109–1114.
Lim U, Wang SS, Hartge P, Cozen W, Kelemen LE, Chanock S et al. Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood 2007; 109: 3050–3059.
Polesel J, Dal Maso L, La Vecchia C, Montella M, Spina M, Crispo A et al. Dietary folate, alcohol consumption, and risk of non-Hodgkin lymphoma. Nutr Cancer 2007; 57: 146–150.
Negri E, Franceschi S, Bosetti C, Levi F, Conti E, Parpinel M et al. Selected micronutrients and oral and pharyngeal cancer. Int J Cancer 2000; 86: 122–127.
Bidoli E, Bosetti C, La Vecchia C, Levi F, Parpinel M, Talamini R et al. Micronutrients and laryngeal cancer risk in Italy and Switzerland: a case-control study. Cancer Causes Control 2003; 14: 477–484.
Zhang SM, Willett WC, Selhub J, Hunter DJ, Giovannucci EL, Holmes MD et al. Plasma folate, vitamin B6, vitamin B12, homocysteine, and risk of breast cancer. J Natl Cancer Inst 2003; 95: 373–380.
Lajous M, Lazcano-Ponce E, Hernandez-Avila M, Willett W, Romieu I . Folate vitamin B(6), and vitamin B(12) intake and the risk of breast cancer among Mexican women. Cancer Epidemiol Biomarkers Prev 2006; 15: 443–448.
Lin J, Lee IM, Cook NR, Selhub J, Manson JE, Buring JE et al. Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. Am J Clin Nutr 2008; 87: 734–743.
Zhang SM, Cook NR, Albert CM, Gaziano JM, Buring JE, Manson JE . Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial. JAMA 2008; 300: 2012–2021.
Ma E, Iwasaki M, Junko I, Hamada GS, Nishimoto IN, Carvalho SM et al. Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Brazilian women. BMC Cancer 2009; 9: 122.
Ma E, Iwasaki M, Kobayashi M, Kasuga Y, Yokoyama S, Onuma H et al. Dietary intake of folate, vitamin B2, vitamin B6, vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Japan. Nutr Cancer 2009; 61: 447–456.
Chou YC, Chu CH, Wu MH, Hsu GC, Yang T, Chou WY et al. Dietary intake of vitamin B(6) and risk of breast cancer in Taiwanese women. J Epidemiol 2011; 21: 329–336.
Zhang CX, Ho SC, Chen YM, Lin FY, Fu JH, Cheng SZ . Dietary folate, vitamin B6, vitamin B12 and methionine intake and the risk of breast cancer by oestrogen and progesterone receptor status. Br J Nutr 2011; 106: 936–943.
Lurie G, Wilkens LR, Shvetsov YB, Ollberding NJ, Franke AA, Henderson BE et al. Prediagnostic plasma pyridoxal 5′-phosphate (vitamin b6) levels and invasive breast carcinoma risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2012; 21: 1942–1948.
Shi Q, Zhang Z, Li G, Pillow PC, Hernandez LM, Spitz MR et al. Sex differences in risk of lung cancer associated with methylene-tetrahydrofolate reductase polymorphisms. Cancer Epidemiol Biomarkers Prev 2005; 14: 1477–1484.
Johansson M, Relton C, Ueland PM, Vollset SE, Midttun O, Nygard O et al. Serum B vitamin levels and risk of lung cancer. JAMA 2010; 303: 2377–2385.
Harrison LE, Zhang ZF, Karpeh MS, Sun M, Kurtz RC . The role of dietary factors in the intestinal and diffuse histologic subtypes of gastric adenocarcinoma: a case-control study in the US. Cancer 1997; 80: 1021–1028.
Zhang ZF, Kurtz RC, Yu GP, Sun M, Gargon N, Karpeh M et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer 1997; 27: 298–309.
Kaaks R, Tuyns AJ, Haelterman M, Riboli E . Nutrient intake patterns and gastric cancer risk: a case-control study in Belgium. Int J Cancer 1998; 78: 415–420.
Mayne ST, Risch HA, Dubrow R, Chow WH, Gammon MD, Vaughan TL et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 1055–1062.
Galeone C, Pelucchi C, Levi F, Negri E, Talamini R, Franceschi S et al. Folate intake and squamous-cell carcinoma of the oesophagus in Italian and Swiss men. Ann Oncol 2006; 17: 521–525.
Pelucchi C, Tramacere I, Bertuccio P, Tavani A, Negri E, La Vecchia C . Dietary intake of selected micronutrients and gastric cancer risk: an Italian case-control study. Ann Oncol 2009; 20: 160–165.
Eussen SJ, Vollset SE, Hustad S, Midttun O, Meyer K, Fredriksen A et al. Vitamins B2 and B6 and genetic polymorphisms related to one-carbon metabolism as risk factors for gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2010; 19: 28–38.
Schernhammer E, Wolpin B, Rifai N, Cochrane B, Manson JA, Ma J et al. Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts. Cancer Res 2007; 67: 5553–5560.
Gong Z, Holly EA, Bracci PM . Intake of folate, vitamins B6, B12 and methionine and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 2009; 20: 1317–1325.
Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M . Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 513–518.
Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A . B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002; 13: 239–248.
Boyapati SM, Bostick RM, McGlynn KA, Fina MF, Roufail WM, Geisinger KR et al. Folate intake, MTHFR C677T polymorphism, alcohol consumption, and risk for sporadic colorectal adenoma (United States). Cancer Causes Control 2004; 15: 493–501.
Larsson SC, Giovannucci E, Wolk A . Vitamin B6 intake, alcohol consumption, and colorectal cancer: a longitudinal population-based cohort of women. Gastroenterology 2005; 128: 1830–1837.
Otani T, Iwasaki M, Hanaoka T, Kobayashi M, Ishihara J, Natsukawa S et al. Folate, vitamin B6, vitamin B12, and vitamin B2 intake, genetic polymorphisms of related enzymes, and risk of colorectal cancer in a hospital-based case-control study in Japan. Nutr Cancer 2005; 53: 42–50.
Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME . Nutritional risks and colorectal cancer in a Portuguese population. Nutr Hosp 2005; 20: 165–172.
Wei EK, Giovannucci E, Selhub J, Fuchs CS, Hankinson SE, Ma J . Plasma vitamin B6 and the risk of colorectal cancer and adenoma in women. J Natl Cancer Inst 2005; 97: 684–692.
Kune G, Watson L . Colorectal cancer protective effects and the dietary micronutrients folate, methionine, vitamins B6, B12, C, E, selenium, and lycopene. Nutr Cancer 2006; 56: 11–21.
Zhang SM, Moore SC, Lin J, Cook NR, Manson JE, Lee IM et al. Folate, vitamin B6, multivitamin supplements, and colorectal cancer risk in women. Am J Epidemiol 2006; 163: 108–115.
Hubner RA, Liu JF, Sellick GS, Logan RF, Houlston RS, Muir KR . Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma. Br J Cancer 2007; 97: 1449–1456.
Ishihara J, Otani T, Inoue M, Iwasaki M, Sasazuki S, Tsugane S . Low intake of vitamin B-6 is associated with increased risk of colorectal cancer in Japanese men. J Nutr 2007; 137: 1808–1814.
Figueiredo JC, Levine AJ, Grau MV, Midttun O, Ueland PM, Ahnen DJ et al. Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. Cancer Epidemiol Biomarkers Prev 2008; 17: 2136–2145.
Schernhammer ES, Giovannuccci E, Fuchs CS, Ogino S . A prospective study of dietary folate and vitamin B and colon cancer according to microsatellite instability and KRAS mutational status. Cancer Epidemiol Biomarkers Prev 2008; 17: 2895–2898.
Schernhammer ES, Ogino S, Fuchs CS . Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expression. Gastroenterology 2008; 135: 770–780.
Sharp L, Little J, Brockton NT, Cotton SC, Masson LF, Haites NE et al. Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene, intakes of folate and related B vitamins and colorectal cancer: a case-control study in a population with relatively low folate intake. Br J Nutr 2008; 99: 379–389.
Theodoratou E, Farrington SM, Tenesa A, McNeill G, Cetnarskyj R, Barnetson RA et al. Dietary vitamin B6 intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 171–182.
Weinstein SJ, Albanes D, Selhub J, Graubard B, Lim U, Taylor PR et al. One-carbon metabolism biomarkers and risk of colon and rectal cancers. Cancer Epidemiol Biomarkers Prev 2008; 17: 3233–3240.
Le Marchand L, White KK, Nomura AM, Wilkens LR, Selhub JS, Tiirikainen M et al. Plasma levels of B vitamins and colorectal cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2009; 18: 2195–2201.
Lee JE, Li H, Giovannucci E, Lee IM, Selhub J, Stampfer M et al. Prospective study of plasma vitamin B6 and risk of colorectal cancer in men. Cancer Epidemiol Biomarkers Prev 2009; 18: 1197–1202.
Eussen SJ, Vollset SE, Hustad S, Midttun O, Meyer K, Fredriksen A et al. Plasma vitamins B2, B6, and B12, and related genetic variants as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2010; 19: 2549–2561.
de Vogel S, Schneede J, Ueland PM, Vollset SE, Meyer K, Fredriksen A et al. Biomarkers related to one-carbon metabolism as potential risk factors for distal colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2011; 20: 1726–1735.
Le Marchand L, Wang H, Selhub J, Vogt TM, Yokochi L, Decker R . Association of plasma vitamin B6 with risk of colorectal adenoma in a multiethnic case-control study. Cancer Causes Control 2011; 22: 929–936.
Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S . B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). PLoS ONE 2011; 6: e21102.
Banque M, Raido B, Masuet C, Ramon JM . Food groups and nutrient intake and risk of colorectal cancer: a hospital-based case-control study in Spain. Nutr Cancer 2012; 64: 386–392.
Zhang X, Lee JE, Ma J, Je Y, Wu K, Willett WC et al. Prospective cohort studies of vitamin B-6 intake and colorectal cancer incidence: modification by time? Am J Clin Nutr 2012; 96: 874–881.
Bosetti C, Scotti L, Maso LD, Talamini R, Montella M, Negri E et al. Micronutrients and the risk of renal cell cancer: a case-control study from Italy. Int J Cancer 2007; 120: 892–896.
Garcia-Closas R, Garcia-Closas M, Kogevinas M, Malats N, Silverman D, Serra C et al. Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. Eur J Cancer 2007; 43: 1731–1740.
Hotaling JM, Wright JL, Pocobelli G, Bhatti P, Porter MP, White E . Long-term use of supplemental vitamins and minerals does not reduce the risk of urothelial cell carcinoma of the bladder in the VITamins And Lifestyle study. J Urol 2011; 185: 1210–1215.
Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT . A case-control study of diet and prostate cancer. Br J Cancer 1997; 76: 678–687.
Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R, Pietinen P, Barrett MJ, Taylor PR et al. Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev 2003; 12: 1271–1272.
Vidal AC, Grant DJ, Williams CD, Masko E, Allott EH, Shuler K et al. Associations between Intake of Folate, Methionine, and Vitamins B-12, B-6 and Prostate Cancer Risk in American Veterans. J Cancer Epidemiol 2012; 2012: 957467.
Kotsopoulos J, Hecht JL, Marotti JD, Kelemen LE, Tworoger SS . Relationship between dietary and supplemental intake of folate, methionine, vitamin B6 and folate receptor alpha expression in ovarian tumors. Int J Cancer 2010; 126: 2191–2198.
Harris HR, Cramer DW, Vitonis AF, DePari M, Terry KL . Folate vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer 2012; 131: E518–E529.
Ames BN . Micronutrient deficiencies. A major cause of DNA damage. Ann NY Acad Sci 1999; 889: 87–106.
Ames BN . DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res 2001; 475: 7–20.
Hong S-W, Lee S-H, Moon J-H, Hwang J-J, Kim D-E, Ko E et al. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 2013; 32: 1508–1517.
Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH . Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004; 64: 5891–5896.
Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK et al. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 2008; 27: 4324–4335.
McCullough ML, Giovannucci EL . Diet and cancer prevention. Oncogene 2004; 23: 6349–6364.
Galluzzi L, Larochette N, Zamzami N, Kroemer G . Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006; 25: 4812–4830.
Adler V, Yin Z, Tew KD, Ronai Z . Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999; 18: 6104–6111.
Frohlich DA, McCabe MT, Arnold RS, Day ML . The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 2008; 27: 4353–4362.
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G . The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11: 215–233.
Zitvogel L, Tesniere A, Kroemer G . Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715–727.
Vitale I, Galluzzi L, Castedo M, Kroemer G . Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12: 385–392.
Acknowledgements
We acknowledge the valuable help of Federico Pietrocola for the compilation of Table 1. The authors are supported by the European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisée); Fondation pour la Recherche Médicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Cancéropôle Ile-de-France and Paris Alliance of Cancer Research Institutes (PACRI).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Galluzzi, L., Vacchelli, E., Michels, J. et al. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene 32, 4995–5004 (2013). https://doi.org/10.1038/onc.2012.623
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.623
Keywords
This article is cited by
-
Vitamin B6 deficiency cooperates with oncogenic Ras to induce malignant tumors in Drosophila
Cell Death & Disease (2024)
-
Circular RNA pyridoxal kinase (circPDXK) involves in the progression of ovarian cancer and glycolysis via regulating miR-654-3p and hexokinase II
Applied Biological Chemistry (2022)
-
Pyroptosis and pyroptosis-inducing cancer drugs
Acta Pharmacologica Sinica (2022)
-
Micronutritional status after pylorus preserving duodenopancreatectomy: analysis of data from a randomized controlled trial
Scientific Reports (2021)
-
Dietary nutrient intake related to higher grade cervical intraepithelial neoplasia risk: a Chinese population-based study
Nutrition & Metabolism (2020)